The Road to Cures Through Immunotherapy and Precision Medicine

Activity Overview

A virtual satellite symposium preceding the 63rd ASH Annual meeting.

Credit Expired

0.25 CE Credit(s)

Expires: December 11, 2021

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies
Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia
Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma
Assess how novel therapeutic strategies lead to improved survival in myeloma
Analyze the impact of COVID-19 and its effect on therapy and outcomes in blood cancer patients

Activity Faculty

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, MA

Lee Greenberger, PhD

Chief Scientific Officer
The Leukemia & Lymphoma Society
Rye Brook, NY

Carl June, MD

Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA